GlaxoSmithKline - Top 10 Layoffs of 2010

Company: GlaxoSmithKline
Layoffs: 5,201

Scoop: CEO Andrew Witty spent the year finding cost-saving options for the company, including laying off workers in Europe and the U.S., including 700 from the sales and marketing division. GSK believes the future is in emerging markets, particularly in Asia and South America, and its transferring much of its muster into those areas with numerous deals.

But beyond layoffs, Witty looked at other failing strategies, including spending £3 billion in nine years on research that found no new products.

GlaxoSmithKline - Top 10 Layoffs of 2010
Read more on

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.